UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 

 

 

 

 

FORM 8-K

 

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): March 3, 2020

 

 

 

 

 

 

ELECTROMED, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Minnesota

001-34839

41-1732920

(State or Other Jurisdiction of

Incorporation)

(Commission File Number)

(I.R.S. Employer Identification

Number)

 

500 Sixth Avenue NW

New Prague, MN 56071

(Address of Principal Executive Offices)(Zip Code)

 

(952) 758-9299

(Registrant’s Telephone Number, Including Area Code)

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

 

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

 

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

 

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Common Stock, $0.01 par value

 

ELMD

 

NYSE American LLC

(Title of each class)

 

(Trading Symbol)

 

(Name of each exchange on which registered)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.                                                                         Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ☐

 

 

 

 

 

 

Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 3, 2020, Jeremy T. Brock, our current Chief Financial Officer, notified that he intends to resign his employment with us on or about July 1, 2020 to pursue other opportunities. The Board of Directors is commencing a search for his successor.

Item 7.01Regulation FD Disclosure..

 

The text of our press release announcing Mr. Brock’s departure is set forth in Exhibit 99.1 to this report and is incorporated by reference into this Item 7.01.

 

Item 9.01Financial Statements and Exhibits.

(d) Exhibits:

Number   Description   Method of Filing
99.1   Press Release dated March 4, 2020   Furnished Electronically
         

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

   ELECTROMED, INC.   
        
Date:  March 4, 2020 By:       /s/ Kathleen S. Skarvan   
   Name:   Kathleen S. Skarvan   
   Title:   President and Chief Executive Officer   

 

 

Exhibit 99.1

 

image

 

 

 

FOR IMMEDIATE RELEASE

 

 

Electromed, Inc. Announces CFO Transition

 

New Prague, Minnesota – March 4, 2020 – Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that CFO Jeremy Brock has elected to pursue other opportunities and the Company and Mr. Brock have established a transition plan. Mr. Brock will continue in the role of CFO until July 1, 2020. Electromed has commenced a national search process to identify and recruit its next CFO.

 

Kathleen Skarvan, Electromed’s President and CEO, commented, "I would like to thank Jeremy for his leadership and many contributions to Electromed over the past eight years. He helped build a strong financial team and rigorous processes to support the growth of our business. We appreciate his willingness to assist during the CFO transition and know that he will be successful in his next endeavors.”

 

Mr. Brock added, "It has been rewarding to help build a vibrant business with Kathleen and the team. As a committed shareholder, I look forward to a bright future for Electromed in the years to come.”

 

 

About Electromed, Inc.

Electromed, Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest® Airway Clearance System, to patients with compromised pulmonary function. The Company is headquartered in New Prague, Minnesota and was founded in 1992.  Further information about the Company can be found at www.smartvest.com.

 

Contacts:    
     
Electromed, Inc.   The Equity Group Inc.
Kathleen Skarvan, President and Chief Executive Officer   Kalle Ahl, CFA
(952) 758-9299   (212) 836-9614
investorrelations@electromed.com   kahl@equityny.com
     
    Devin Sullivan
    (212) 836-9608
    dsullivan@equityny.com
           

###